Bartosińska Joanna, Michalak-Stoma Anna, Kowal Małgorzata, Raczkiewicz Dorota, Krasowska Dorota, Chodorowska Grażyna, Giannopoulos Krzysztof
Department of Dermatology, Venereology and Paediatric Dermatology, Medical University of Lublin, Lublin, Poland.
Institute of Statistics and Demography, Warsaw School of Economics, Warsaw, Poland.
Postepy Dermatol Alergol. 2019 Apr;36(2):167-172. doi: 10.5114/ada.2018.73329. Epub 2018 Feb 5.
Circulating soluble programmed death 1 (PD-1), neuropilin 1 (NRP-1) and human leukocyte antigen-G (HLA-G) take part in modulating immune tolerance causing disturbances in the molecular mechanisms responsible for maintenance of balance between effector and regulatory components of the immune system. Since their cell-surface expression levels were found to be changed in lesional and/or non-lesional skin of psoriatic patients, analysis of soluble PD-1, NRP-1 and HLA-G concentrations sheds more light on their role in detecting unbalanced immune tolerance in psoriasis.
To assess soluble PD-1, NRP-1 and HLA-G concentrations in psoriasis.
The study included 57 psoriatic patients and 29 controls. Duration of psoriasis was in the range 1 to 55 years; the median was 19 years. The plasma concentrations of soluble HLA-G (sHLA-G), soluble NRP-1 (sNRP-1) and soluble PD-1 (sPD-1) were examined using the ELISA method. Severity of the skin lesions was assessed by means of Psoriasis Area Severity Index (PASI), body surface area (BSA) and Physician Global Assessment (PGA).
Psoriasis Area Severity Index in the studied group was in the range 3 to 43; the median was 12. Body surface area was in the range 2-75%; the median was 15%. The median value of PGA was 3. Soluble NRP concentration was significantly higher in the psoriatic patients (median: 1.59 pg/ml; range: 0.67-2.62 pg/ml) than in the control group (median: 1.35 pg/ml; range: 0.05-2.61 pg/ml) ( = 0.010). Soluble PD-1 and sHLA-G concentrations were not significantly different between the studied and control groups ( = 0.094 and = 0.482, respectively).
Increased concentrations of sNRP-1 and unchanged values of sHLA-G and sPD-1 concentrations may be indicative of impaired immune tolerance mechanisms in psoriasis.
循环可溶性程序性死亡蛋白1（PD-1）、神经纤毛蛋白1（NRP-1）和人类白细胞抗原G（HLA-G）参与调节免疫耐受，导致负责维持免疫系统效应和调节成分之间平衡的分子机制紊乱。由于发现银屑病患者皮损和/或非皮损皮肤中它们的细胞表面表达水平发生了变化，因此分析可溶性PD-1、NRP-1和HLA-G的浓度有助于更深入了解它们在检测银屑病中免疫耐受失衡方面的作用。
评估银屑病患者中可溶性PD-1、NRP-1和HLA-G的浓度。
该研究纳入了57例银屑病患者和29例对照。银屑病病程为1至55年；中位数为19年。采用酶联免疫吸附测定（ELISA）法检测血浆中可溶性HLA-G（sHLA-G）、可溶性NRP-1（sNRP-1）和可溶性PD-1（sPD-1）的浓度。通过银屑病面积和严重程度指数（PASI）、体表面积（BSA）和医生整体评估（PGA）评估皮肤病变的严重程度。
研究组的银屑病面积和严重程度指数范围为3至43；中位数为12。体表面积范围为2%至75%；中位数为15%。PGA的中位数为3。银屑病患者的可溶性NRP浓度（中位数：1.59 pg/ml；范围：0.67至2.62 pg/ml）显著高于对照组（中位数：1.35 pg/ml；范围：0.05至2.61 pg/ml）（P = 0.010）。研究组和对照组之间的可溶性PD-1和sHLA-G浓度无显著差异（分别为P = 0.094和P = 0.482）。
sNRP-1浓度升高以及sHLA-G和sPD-1浓度无变化可能表明银屑病患者的免疫耐受机制受损。
